BONESUPPORT HOLDING AB (BOEUF)

Overview

Bonesupport Holding AB (publ) is an innovator in the field of orthobiologics, focusing on the development and global marketing of injectable bio-ceramic bone graft substitutes. Founded in 1999 and headquartered in Lund, Sweden, the company has established its footprint across Europe, North America, and other international markets. By leveraging advanced ceramic materials that mimic the properties of human bone, Bonesupport addresses a critical need in the medical field for effective bone repair and regeneration solutions. Its product pipeline is designed to support a range of bone healing processes, from addressing bone voids to combating bone infections, highlighting the company's commitment to enhancing orthopedic care and patient outcomes.

Products and Services

• CERAMENT Bone Void Filler

  An injectable ceramic bone graft substitute designed to closely mimic the healing properties of natural bone. Upon injection, it remodels into the host bone, facilitating effective bone regeneration in voids or gaps caused by surgery or injury.

• CERAMENT G

  This version of the bone graft substitute not only remodels to host bone but also elutes Gentamicin, a potent antibiotic, during the first 30 days of bone healing. It is particularly beneficial in treating and preventing bone infections, offering a dual-action solution in bone regeneration and infection control.

• CERAMENT V

  Similar to CERAMENT G, this injectable bio-ceramic bone graft delivers Vancomycin, another powerful antibiotic, while also promoting bone regeneration. CERAMENT V targets the critical initial phase of bone healing, providing both infection prevention and treatment, making it a crucial tool in the management of bone infections.

• CERAMENT Bead Tray

  A specialized delivery system for local administration of the CERAMENT bone graft substitute. It allows surgeons to precisely target osseous defects and manage dead spaces within the bone, ensuring localized and effective treatment. This adjunctive option enhances surgical flexibility and outcomes in bone defect management.

In addition to its commercial products, Bonesupport is committed to further innovation, with a pipeline of preclinical product candidates focused on promoting bone regrowth across various conditions, including trauma, chronic osteomyelitis, and surgeries related to revision arthroplasty and foot and ankle. This forward-looking approach underscores the company's dedication to addressing unmet needs in orthopedic surgery and bone healing.